- Home
- VTGN vs QNCX Comparison
VTGN vs QNCX Comparison
Compare VTGN & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VTGN | QNCX |
|---|---|---|
| Founded | 1998 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.1M | 19.9M |
| IPO Year | 2014 | 2019 |
Fundamental Metrics
Financial Performance| Metric | VTGN | QNCX |
|---|---|---|
| Price | $0.69 | $0.90 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 3 | 2 |
| Target Price | ★ $0.90 | N/A |
| AVG Volume (30 Days) | ★ 820.6K | 690.4K |
| Earning Date | 06-16-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.88 |
| Revenue | N/A | ★ N/A |
| Revenue This Year | $124.49 | N/A |
| Revenue Next Year | $353.99 | N/A |
| P/E Ratio | ★ N/A | $0.31 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.43 | $0.08 |
| 52 Week High | $5.14 | $4.55 |
Technical Indicators
Market Signals| Indicator | VTGN | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 64.14 | 46.24 |
| Support Level | $0.54 | $0.79 |
| Resistance Level | $0.77 | $0.98 |
| Average True Range (ATR) | 0.06 | 0.07 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 79.43 | 29.96 |
Price Performance
Historical ComparisonAbout VTGN VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.